Profile data is unavailable for this security.
About the company
Barinthus Biotherapeutics plc, formerly Vaccitech plc, is a clinical-stage biopharmaceutical company. It is focused on developing novel T cell immunotherapeutic that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. Its four platform technologies include ChAdOx, MVA, SNAP-TI, and SNAP-CI. It is advancing a pipeline of five product candidates across a range of therapeutic areas, including VTP-300, an immunotherapeutic candidate designed as a potential component of a functional cure for chronic HBV infection; VTP-200, a non-surgical product candidate for persistent high-risk human papillomavirus (HPV); VTP-1000, an autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease; VTP-850, a second-generation immunotherapeutic candidate designed to treat recurrent prostate cancer, and VTP-1100, a preclinical cancer candidate designed to utilize the SNAP-CI platform to treat patients with HPV-related cancer.
- Revenue in USD (TTM)334.00k
- Net income in USD-70.66m
- Incorporated2021
- Employees130.00
- LocationBarinthus Biotherapeutics PLCThe Schrdinger BuildingHeatley Road, The Oxford Science ParkDIDCOT OX11 0DFUnited KingdomGBR
- Phone+44 186 581 8808
- Websitehttps://www.barinthusbio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Passage Bio Inc | 0.00 | -84.44m | 70.27m | 58.00 | -- | 0.6697 | -- | -- | -1.53 | -1.53 | 0.00 | 1.70 | 0.00 | -- | -- | 0.00 | -47.73 | -48.56 | -52.17 | -52.09 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 25.02 | -- | -43.53 | -- |
| Provectus Biopharmaceuticals Inc | 590.75k | -2.78m | 71.32m | 4.00 | -- | -- | -- | 120.73 | -0.0066 | -0.0066 | 0.0014 | -0.0178 | 0.4221 | -- | 1,358.05 | 147,687.50 | -198.50 | -276.33 | -- | -- | -- | -- | -470.31 | -1,667.76 | -- | -10.24 | -- | -- | -43.61 | -- | 12.74 | -- | -- | -- |
| Benitec Biopharma Inc | 7.00k | -21.69m | 71.66m | 18.00 | -- | 1.81 | -- | 10,237.32 | -9.87 | -9.87 | 0.0031 | 4.22 | 0.0006 | -- | 0.1284 | 388.89 | -186.85 | -83.43 | -260.89 | -98.77 | 1,542.86 | 96.86 | -309,885.70 | -468.04 | -- | -307.03 | 0.00 | -- | 2.74 | -53.84 | -7.44 | -- | -56.51 | -- |
| Alpha Teknova Inc | 36.85m | -36.06m | 71.85m | 210.00 | -- | 0.8617 | -- | 1.95 | -1.05 | -1.05 | 1.05 | 2.04 | 0.2815 | 2.29 | 7.89 | 175,490.50 | -27.54 | -- | -29.30 | -- | 27.36 | -- | -97.85 | -- | 3.92 | -28.23 | 0.1365 | -- | -11.43 | -- | 22.52 | -- | -- | -- |
| Bioatla Inc | 0.00 | -119.24m | 72.66m | 65.00 | -- | 1.46 | -- | -- | -2.49 | -2.49 | 0.00 | 1.03 | 0.00 | -- | -- | 0.00 | -81.18 | -48.72 | -96.07 | -57.35 | -- | -- | -- | -6,651.71 | -- | -- | 0.00 | -- | -- | -- | -15.95 | -- | -37.01 | -- |
| Annovis Bio Inc | 0.00 | -47.53m | 73.17m | 6.00 | -- | -- | -- | -- | -5.04 | -5.04 | 0.00 | -0.3046 | 0.00 | -- | -- | 0.00 | -284.97 | -106.31 | -411.92 | -124.71 | -- | -- | -- | -- | -- | -9.20 | -- | -- | -- | -- | -121.90 | -- | -- | -- |
| Aclaris Therapeutics Inc | 31.12m | -77.26m | 73.40m | 91.00 | -- | 0.5168 | -- | 2.36 | -1.09 | -1.09 | 0.4392 | 1.99 | 0.1541 | -- | 58.77 | 341,967.00 | -38.27 | -47.29 | -42.29 | -53.87 | 41.99 | 44.00 | -248.28 | -549.18 | -- | -- | 0.00 | -- | 5.03 | 38.41 | -1.81 | -- | -0.703 | -- |
| Tempest Therapeutics Inc | 0.00 | -29.76m | 73.76m | 17.00 | -- | 3.58 | -- | -- | -1.76 | -1.76 | 0.00 | 0.9287 | 0.00 | -- | -- | 0.00 | -72.84 | -57.10 | -93.72 | -71.20 | -- | -- | -- | -- | -- | -141.39 | 0.3394 | -- | -- | -- | 17.41 | -- | 36.40 | -- |
| Barinthus Biotherapeutics PLC - ADR | 334.00k | -70.66m | 74.55m | 130.00 | -- | 0.433 | -- | 223.21 | -1.83 | -1.83 | 0.0087 | 4.41 | 0.0015 | -- | 0.0676 | 2,569.23 | -30.67 | -- | -32.45 | -- | -- | -- | -21,180.84 | -- | -- | -- | 0.00 | -- | -98.21 | -- | -1,473.03 | -- | -- | -- |
| MDxHealth SA - ADR | 75.33m | -39.90m | 75.04m | 300.00 | -- | -- | -- | 0.9962 | -1.14 | -1.14 | 0.8428 | -0.0357 | 0.5528 | 11.06 | 6.95 | 251,090.00 | -29.28 | -51.62 | -33.98 | -64.72 | 62.76 | 50.88 | -52.97 | -117.64 | 1.53 | -1.54 | 1.02 | -- | 89.43 | 19.84 | 2.14 | -- | 30.13 | -- |
| Bakhu Holdings Corp | 0.00 | -1.92m | 75.33m | 2.00 | -- | -- | -- | -- | -0.0064 | -0.0064 | 0.00 | -0.0325 | 0.00 | -- | -- | 0.00 | -281.75 | -4,391.82 | -- | -- | -- | -- | -- | -- | -- | -8.39 | -- | -- | -- | -- | 33.37 | -- | -- | -- |
| Spero Therapeutics Inc | 110.98m | 23.40m | 76.66m | 46.00 | 3.37 | 0.7948 | 3.24 | 0.6908 | 0.4213 | 0.4213 | 2.08 | 1.79 | 0.792 | -- | 3.96 | 2,412,565.00 | 16.70 | -35.52 | 21.73 | -41.75 | -- | -- | 21.09 | -124.40 | -- | -- | 0.00 | -- | 93.95 | 92.11 | 149.14 | -- | -- | -- |
| Anixa Biosciences Inc | 210.00k | -10.74m | 77.52m | 4.00 | -- | 3.14 | -- | 369.13 | -0.3451 | -0.3451 | 0.0068 | 0.7749 | 0.0078 | -- | 0.7807 | 52,500.00 | -40.49 | -59.69 | -41.26 | -62.61 | -- | -- | -5,174.29 | -6,040.10 | -- | -- | 0.00 | -- | -- | -28.36 | 27.83 | -- | -- | -- |
| IO Biotech Inc | 0.00 | -88.50m | 77.74m | 68.00 | -- | 0.6733 | -- | -- | -1.86 | -1.86 | 0.00 | 1.75 | 0.00 | -- | -- | 0.00 | -66.79 | -- | -72.66 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -20.47 | -- | -- | -- |
| Marinus Pharmaceuticals Inc | 28.29m | -145.34m | 78.01m | 165.00 | -- | -- | -- | 2.76 | -2.64 | -2.64 | 0.5142 | -0.2992 | 0.1554 | 0.8536 | 3.72 | 171,442.40 | -79.82 | -49.64 | -96.93 | -57.76 | 91.22 | -- | -513.80 | -518.96 | 2.93 | -13.62 | 1.29 | -- | 21.63 | -- | -613.59 | -- | 7.47 | -- |
| Cognition Therapeutics Inc | 0.00 | -28.77m | 78.11m | 25.00 | -- | 2.70 | -- | -- | -0.9155 | -0.9155 | 0.00 | 0.7218 | 0.00 | -- | -- | 0.00 | -68.08 | -- | -85.18 | -- | -- | -- | -- | -- | -- | -251.59 | 0.00 | -- | -- | -- | -20.52 | -- | -- | -- |
Data as of May 31 2024. Currency figures normalised to Barinthus Biotherapeutics PLC's reporting currency: US Dollar USD
17.54%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| M&G Investment Management Ltd.as of 31 Mar 2024 | 5.20m | 13.48% |
| DC Investments Management LLCas of 31 Mar 2024 | 642.20k | 1.67% |
| BlueCrest Capital Management (UK) LLPas of 31 Mar 2024 | 542.67k | 1.41% |
| Robert W. Baird & Co., Inc. (Private Banking)as of 31 Mar 2024 | 167.71k | 0.44% |
| The Johns Hopkins University (Investment Management)as of 31 Mar 2024 | 122.24k | 0.32% |
| Renaissance Technologies LLCas of 31 Mar 2024 | 27.70k | 0.07% |
| Ipswich Investment Management Co., Inc.as of 31 Mar 2024 | 23.08k | 0.06% |
| Janney Montgomery Scott LLC (Investment Management)as of 31 Mar 2024 | 15.01k | 0.04% |
| Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Mar 2024 | 12.86k | 0.03% |
| Geode Capital Management LLCas of 31 Mar 2024 | 11.57k | 0.03% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
